Meaningful benefit of disease‐modifying treatment: Evaluating changes in health‐related resource use

Abstract

AbstractINTRODUCTIONAre reductions in the rate of decline from the new disease‐modifying treatments (DMTs) in early Alzheimer's disease (AD) meaningful? We examined whether such reductions may be reflected in changes in health‐related resource use.METHODSPatients with Clinical Dementia Rating (CDR) = 0.5 or 1 with a clinical diagnosis of mild cognitive impairment or AD, reflecting clinical trial populations. Health‐related resource use was reported using the Resource Use Inventory (RUI) including direct medical care, non‐medical care, unpaid informal care, and time use.RESULTSFaster decline in CDR–Sum of Boxes (CDR‐SB) from baseline was independently associated with higher likelihood and hours of informal care received, and lower likelihood of employment/volunteer work, but not with direct medical care.DISCUSSIONReductions in the rate of decline in CDR‐SB seen from DMTs significantly affect patients’ work capacity and need for informal care, indicators of economic impact meaningful to patients, families, and health systems. These measures are not readily captured in administrative data sets.Highlights Following a cohort of participants with MCI or mild dementia due to AD that mimics participants targeted for AD trials, this study showed slower decline in CDR‐SB have significant effects on patients’ work capacity and need for informal care, but not on their direct medical care utilization such as hospitalizations, ED use, and doctors’ visits. Capturing potential benefits in health‐related resource use may require direct measures of informal care and work/volunteer effort which are meaningful outcomes to patients, families and health systems. Caution is needed in our effort to assess benefits of recently developed disease modifying treatment in AD using electronic health records and administrative data from which utilization of direct medical care are routinely collected as these data sources may not capture the most apparent changes in resource utilization during early disease stages.